新型冠状病毒感染相关静脉血栓栓塞症的防治

Prevention and Treatment of Venous Thromboembolism Associated with Corona Virus Disease(COVID-19)

新型冠状病毒感染(COVID-19)可通过多种机制引发血栓并发症,其中静脉血栓栓塞症(VTE)是导致COVID-19住院患者死亡或预后不佳的重要原因之一。COVID-19患者的静脉血栓预防需权衡VTE及出血风险。COVID-19患者可能会有凝血功能异常情况,而脏器微血栓、抗凝药物的使用可能会增加出血风险,加重病情。此外,抗凝不充分也会增加重症COVID-19患者的死亡率。因此,尽早启动风险评估、选择适宜的预防和治疗措施对于改善患者预后至关重要。

Corona virus disease(COVID-19)can induce thrombotic complications through a variety of mechanisms,among which venous thromboembolism(VTE)is one of the important causes of death or poor prognosis in hospitalized patients with COVID-19.Venous thromboprophylaxis in COVID-19 patients should be used based on the risks of VTE and bleeding.Patients with COVID-19 may have coagulation disorders,which may be exacerbated by organ microthrombi.Anticoagulants may increase the risk of bleeding.In addition,inadequate anticoagulation may lead to increased mortality in critically ill COVID-19 patients.Therefore,early initiation of risk assessment and selection of appropriate preventive and treatment measures are essential to improve patient outcomes.